Barclays’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $32.1M | Sell |
243,984
-8,257
| -3% | -$1.1M | 0.01% | 896 |
|
|
2025
Q4 | $35.8M | Sell |
252,241
-51,737
| -17% | -$7.5M | 0.01% | 930 |
|
|
2025
Q3 | $42.7M | Buy |
303,978
+32,588
| +12% | +$4.42M | 0.01% | 851 |
|
|
2025
Q2 | $34.1M | Buy |
271,390
+71,172
| +36% | +$8.16M | 0.01% | 869 |
|
|
2025
Q1 | $22.1M | Buy |
200,218
+21,850
| +12% | +$2.77M | 0.01% | 983 |
|
|
2024
Q4 | $24.3M | Sell |
178,368
-3,223
| -2% | -$399K | 0.01% | 1018 |
|
|
2024
Q3 | $20.9M | Buy |
181,591
+19,202
| +12% | +$2.63M | 0.01% | 1047 |
|
|
2024
Q2 | $22.4M | Sell |
162,389
-94,850
| -37% | -$13M | 0.01% | 897 |
|
|
2024
Q1 | $35.5M | Buy |
257,239
+25,071
| +11% | +$3.42M | 0.01% | 747 |
|
|
2023
Q4 | $30.6M | Buy |
232,168
+53,905
| +30% | +$6.2M | 0.01% | 884 |
|
|
2023
Q3 | $20.1M | Sell |
178,263
-16,259
| -8% | -$1.71M | 0.01% | 757 |
|
|
2023
Q2 | $18.3M | Sell |
194,522
-53,472
| -22% | -$5.22M | 0.01% | 755 |
|
|
2023
Q1 | $25.1M | Buy |
247,994
+92,208
| +59% | +$9.6M | 0.01% | 763 |
|
|
2022
Q4 | $18.6M | Buy |
155,786
+9,183
| +6% | +$1.08M | 0.01% | 929 |
|
|
2022
Q3 | $15.6M | Buy |
146,603
+27,837
| +23% | +$2.82M | 0.02% | 698 |
|
|
2022
Q2 | $11.6M | Buy |
118,766
+4,055
| +4% | +$374K | 0.01% | 951 |
|
|
2022
Q1 | $10.8M | Sell |
114,711
-17,676
| -13% | -$1.5M | 0.01% | 878 |
|
|
2021
Q4 | $11.3M | Sell |
132,387
-23,000
| -15% | -$2.12M | ﹤0.01% | 1206 |
|
|
2021
Q3 | $14.9M | Sell |
155,387
-47,617
| -23% | -$4.5M | 0.01% | 1013 |
|
|
2021
Q2 | $19.8M | Buy |
203,004
+127,576
| +169% | +$12.2M | 0.01% | 904 |
|
|
2021
Q1 | $7.33M | Buy |
75,428
+36,573
| +94% | +$3.84M | ﹤0.01% | 1232 |
|
|
2020
Q4 | $3.72M | Sell |
38,855
-33,124
| -46% | -$3.2M | ﹤0.01% | 1732 |
|
|
2020
Q3 | $6.92M | Buy |
71,979
+28,431
| +65% | +$3.29M | ﹤0.01% | 1212 |
|
|
2020
Q2 | $5.31M | Buy |
43,548
+12,558
| +41% | +$1.39M | ﹤0.01% | 1332 |
|
|
2020
Q1 | $2.68M | Sell |
30,990
-40,014
| -56% | -$3.92M | ﹤0.01% | 2013 |
|
|
2019
Q4 | $7.63M | Buy |
71,004
+18,501
| +35% | +$1.94M | ﹤0.01% | 1601 |
|
|
2019
Q3 | $4.73M | Sell |
52,503
-32,557
| -38% | -$3.04M | ﹤0.01% | 1898 |
|
|
2019
Q2 | $7.18M | Buy |
85,060
+1,818
| +2% | +$149K | ﹤0.01% | 1559 |
|
|
2019
Q1 | $7.33M | Buy |
83,242
+6,091
| +8% | +$509K | 0.01% | 1419 |
|
|
2018
Q4 | $5.51M | Buy |
77,151
+52,969
| +219% | +$5.07M | ﹤0.01% | 1529 |
|
|
2018
Q3 | $2.97M | Buy |
24,182
+1,758
| +8% | +$199K | ﹤0.01% | 2420 |
|
|
2018
Q2 | $2.2M | Sell |
22,424
-15,989
| -42% | -$1.43M | ﹤0.01% | 2500 |
|
|
2018
Q1 | $3.19M | Buy |
38,413
+5,274
| +16% | +$445K | ﹤0.01% | 2003 |
|
|
2017
Q4 | $2.57M | Sell |
33,139
-337
| -1% | -$23K | ﹤0.01% | 2212 |
|
|
2017
Q3 | $2.05M | Buy |
33,476
+13,285
| +66% | +$701K | ﹤0.01% | 2338 |
|
|
2017
Q2 | $928K | Buy |
20,191
+9,618
| +91% | +$467K | ﹤0.01% | 2951 |
|
|
2017
Q1 | $458K | Sell |
10,573
-90,042
| -89% | -$3.86M | ﹤0.01% | 3485 |
|
|
2016
Q4 | $3.9M | Buy |
100,615
+93,196
| +1,256% | +$4.22M | ﹤0.01% | 1565 |
|
|
2016
Q3 | $375K | Sell |
7,419
-29,147
| -80% | -$1.45M | ﹤0.01% | 3466 |
|
|
2016
Q2 | $1.66M | Buy |
36,566
+13,129
| +56% | +$604K | ﹤0.01% | 2167 |
|
|
2016
Q1 | $914K | Sell |
23,437
-27,030
| -54% | -$1.07M | ﹤0.01% | 2599 |
|
|
2015
Q4 | $2.83M | Sell |
50,467
-34,791
| -41% | -$1.77M | ﹤0.01% | 1740 |
|
|
2015
Q3 | $3.33M | Buy |
85,258
+65,748
| +337% | +$3.18M | ﹤0.01% | 1661 |
|
|
2015
Q2 | $915K | Sell |
19,510
-6,208
| -24% | -$263K | ﹤0.01% | 2953 |
|
|
2015
Q1 | $1M | Sell |
25,718
-139,358
| -84% | -$4.98M | ﹤0.01% | 2983 |
|
|
2014
Q4 | $3.63M | Buy |
165,076
+12,717
| +8% | +$241K | ﹤0.01% | 1977 |
|
|
2014
Q3 | $2.29M | Buy |
152,359
+106,580
| +233% | +$1.59M | ﹤0.01% | 2542 |
|
|
2014
Q2 | $641K | Buy |
45,779
+14,918
| +48% | +$211K | ﹤0.01% | 3745 |
|
|
2014
Q1 | $494K | Buy |
30,861
+547
| +2% | +$9.36K | ﹤0.01% | 3971 |
|
|
2013
Q4 | $273K | Sell |
30,314
-80,912
| -73% | -$790K | ﹤0.01% | 4691 |
|
|
2013
Q3 | $1.22M | Buy |
111,226
+37,893
| +52% | +$521K | ﹤0.01% | 3126 |
|
|
2013
Q2 | $981K | Buy |
+73,333
| New | +$901K | ﹤0.01% | 3386 |
|
Other funds holding NBIX
VPM
VCM
Barclays's NBIX Position: Q1 2026 in Review
Barclays reduced its Neurocrine Biosciences (NBIX) stake by 3.3% in Q1 2026, selling an estimated $1.1M and leaving 243,984 shares worth $32.1M. The position accounts for 0.01% of the portfolio, ranked #896.
Barclays first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.7M in Q3 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Barclays held 243,984 shares of Neurocrine Biosciences worth $32.1M as of Q1 2026.
- Barclays sold 8,257 Neurocrine Biosciences shares in Q1 2026, an estimated $1.1M.
- Neurocrine Biosciences made up 0.01% of Barclays's portfolio in Q1 2026, its #896 holding.
- Barclays first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Neurocrine Biosciences position peaked at $42.7M in Q3 2025.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.